Independent · Educational · Not medical advice
Navigate peptide therapy without the chaos.
Plain-English guides, provider comparisons, and tracking tools for people considering GLP-1 and peptide-based treatments. We don't sell, prescribe, or endorse — we help you ask better questions.
Latest
Freshest articles
The most recent updates from our editorial team.
- GLP-1 medications linked to reduced physical activity in first large wearable studySafety · 4 min
- GLP-1 medications and your heart and kidneys: what 2026 research showsFoundations · 5 min
- GLP-1 medications and bone density: what a new study found — and what it doesn't proveSafety · 5 min
- What to check before injecting a compounded GLP-1: the FDA's fraud red flagsSafety · 6 min
- Wegovy's $199 starter price ends June 30: what's nextIndustry & Regulation · 5 min
Peptide therapy is going mainstream. The consumer experience hasn't caught up.
Unclear legality
Branded, compounded, and 'research' products are sold side by side with very different legal footing.
Inconsistent provider quality
From async forms to board-certified follow-up — same category, very different oversight.
Bad education
Marketing copy answers most of what people read, and almost none of what they actually need to know.
Doctor-discussion checklist
“Am I ready for a GLP-1 conversation?”
Six questions. Tailored questions to bring to your clinician, a list of red flags to avoid online, and a starter tracking template. No diagnosis, no recommendation.
Take the 2-minute quiz- Questions to ask your clinician
- What to prepare before your appointment
- What not to buy online
- Starter tracking template
Provider transparency
Provider comparison, side by side
Independently researched. Pricing, oversight, and any public FDA or litigation history — surfaced before you sign up.
| Provider | Type | Monthly |
|---|---|---|
| 9amHealth | Branded | $149/mo |
| Amazon One Medical | Branded | $9/mo |
| Calibrate | Branded | $199/mo |
| CVS MinuteClinic Weight Loss | Branded | — |
| Eden | Both | $129/mo |
Last verified by our editorial team. Always confirm details with the provider before deciding.
Cornerstone guides
Start here
Safety
GLP-1 medications linked to reduced physical activity in first large wearable study
A large wearable study at ENDO 2026 found GLP-1 users took fewer daily steps and exercised less after starting treatment. Here’s what the data shows — and why it matters.
4 min read
Foundations
GLP-1 medications and your heart and kidneys: what 2026 research shows
Real-world 2026 data from Nature Medicine suggests GLP-1 medications may protect the heart and kidneys beyond weight loss alone. Here’s what the evidence actually shows — and what it doesn’t.
5 min read
Safety
GLP-1 medications and bone density: what a new study found — and what it doesn't prove
A 2026 Weill Cornell study found greater hip bone loss in people without diabetes who use semaglutide or tirzepatide. Here's what the data actually shows — and what one retrospective study can't establish.
5 min read
Safety
What to check before injecting a compounded GLP-1: the FDA's fraud red flags
The FDA has confirmed fraudulent compounded semaglutide and tirzepatide with false pharmacy labels. Here are the specific red flags to check — and how to verify your pharmacy before your next dose.
6 min read
Industry & Regulation
Wegovy's $199 starter price ends June 30: what's next
Wegovy's introductory $199/month NovoCare savings offer for injectable starter doses expires after June 30, 2026. Here's what current patients face on July 1 and what options exist.
5 min read
The weekly brief
A plain-English brief on GLP-1s, peptides, and the business behind them.
FDA updates, new studies translated, provider and pricing shifts, and one practical tracking tip — in your inbox once a week.